1 |
Wang J, Napoli E, Kim K, McLennan YA, Hagerman RJ, Giulivi C. Brain Atrophy and White Matter Damage Linked to Peripheral Bioenergetic Deficits in the Neurodegenerative Disease FXTAS. Int J Mol Sci 2021;22:9171. [PMID: 34502080 DOI: 10.3390/ijms22179171] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
2 |
Orsucci D, Lorenzetti L, Baldinotti F, Rossi A, Vitolo E, Gheri FL, Napolitano A, Tintori G, Vista M. Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): A Gender Perspective. J Clin Med 2022;11:1002. [PMID: 35207276 DOI: 10.3390/jcm11041002] [Reference Citation Analysis]
|
3 |
Sodhi DK, Hagerman R. Fragile X Premutation: Medications, Therapy and Lifestyle Advice. Pharmgenomics Pers Med 2021;14:1689-99. [PMID: 35002287 DOI: 10.2147/PGPM.S338846] [Reference Citation Analysis]
|
4 |
Johnson D, Santos E, Kim K, Ponzini MD, Mclennan YA, Schneider A, Tassone F, Hagerman RJ. Increased Pain Symptomatology Among Females vs. Males With Fragile X-Associated Tremor/Ataxia Syndrome. Front Psychiatry 2022;12:762915. [DOI: 10.3389/fpsyt.2021.762915] [Reference Citation Analysis]
|
5 |
Famula J, Ferrer E, Hagerman RJ, Tassone F, Schneider A, Rivera SM, Hessl D. Neuropsychological changes in FMR1 premutation carriers and onset of fragile X-associated tremor/ataxia syndrome. J Neurodev Disord 2022;14:23. [PMID: 35321639 DOI: 10.1186/s11689-022-09436-y] [Reference Citation Analysis]
|